WHAT FDA APPROVALS AND WADA STATUS MEAN FOR YOU

1.FDA status categories explained

FDA Approved means a compound has completed Phase I, II, and III clinical trials demonstrating safety and efficacy for a specific indication, received NDA or BLA approval, and can be legally manufactured and sold as a drug in the United States. Examples relevant to peptide users: semaglutide (approved as Ozempic and Wegovy), tirzepatide (Mounjaro, Zepbound). No currently available research peptides for healing or GH stimulation carry FDA approval.

Compounding Allowed is a fluid category managed through USP regulations and FDA oversight. Licensed compounding pharmacies can produce non-FDA-approved peptides and FDA-approved drugs in customized formulations when prescribed by a physician. This is the legal pathway for accessing pharmaceutical-grade BPC-157, TB-500, and similar healing peptides in the US — though availability varies by state and pharmacy.

Research Only — Not for Human Use is the regulatory position of most research peptides. The compound exists in the literature, may have been studied in animals and early human trials, but has not gone through the FDA approval process. It can be legally sold for research purposes without human-use marketing. This covers the vast majority of the peptide category: ipamorelin, CJC-1295, Selank, Semax, Epithalon, Thymosin Alpha-1, and many others.

Scheduled substances are explicitly classified under the Controlled Substances Act. Some peptide-adjacent compounds are scheduled: certain growth hormone secretagogues have been specifically scheduled, EPO is explicitly banned under FDCA, and some melanocortin peptides have complex regulatory status. Confirm the current scheduling status of any peptide before ordering if you have concerns about legal exposure.

The most dynamic area currently is GLP-1 compounding. The FDA allowed expanded compounding of semaglutide and tirzepatide during shortage periods from 2023-2025. As brand-name supply stabilizes, FDA has moved to restrict this compounding window. The regulatory status of compounded GLP-1s is actively changing and requires current research before assuming availability.

2.What the WADA prohibited list actually covers

The World Anti-Doping Agency maintains the Prohibited List — a document updated annually that specifies substances banned in sport, either in-competition only, out-of-competition, or year-round. WADA status has nothing to do with legality or safety. It is exclusively about sports eligibility for athletes competing in WADA-signatory sports.

WADA prohibits all peptide hormones and their releasing factors in the hormone and metabolic modulators category: this includes all GHRH analogs (CJC-1295), all GHRPs (ipamorelin, GHRP-2, GHRP-6), IGF-1 and analogs, GH itself, EPO and analogs, and mechano growth factors. If it amplifies growth hormone or IGF-1, it is almost certainly on the WADA list.

The BPC-157 situation is notable: as of the most recent WADA prohibited list, BPC-157 is not explicitly listed. However, WADA includes language about 'other peptides with similar biological effects' that could encompass it under a broader interpretation. Athletes should consult with their national anti-doping organization before using any peptide.

GLP-1 agonists occupy a complex space. Semaglutide and tirzepatide have been discussed for potential WADA listing due to their body composition and metabolic effects in athletes. As of 2026, they remain unlisted but are under monitoring program review. This could change.

For the majority of peptide users who do not compete in organized, tested sports, WADA status is irrelevant. For anyone who does compete — even in recreational WADA-affiliated events, masters competitions, powerlifting federations with testing, or Olympic sports at any level — the WADA list determines what you can and cannot use without risk of sanction.

Testing technology matters here. WADA's detection methods improve annually. Compounds that were 'undetectable' years ago are now routinely caught. Assuming a peptide cannot be detected is not a reliable risk management strategy for athletes who compete in tested sports.

3.Compounding pharmacies and the 2026 landscape

Compounding pharmacies provide the legal bridge between a physician's assessment of your needs and access to pharmaceutical-grade peptides without FDA drug approval. Under Section 503A of the Food, Drug, and Cosmetic Act, a licensed compounding pharmacy can prepare a peptide for a specific patient with a valid prescription. Under Section 503B, outsourcing facilities can compound at scale for healthcare facilities.

The practical pathway: find a physician (telehealth clinics have made this more accessible) who is familiar with peptide protocols. With a prescription, a licensed 503A pharmacy can compound BPC-157, TB-500, CJC-1295, ipamorelin, thymosin alpha-1, and many others. The compound arrives in a vial with pharmaceutical-grade documentation, endotoxin testing, and sterility assurance.

Cost comparison: compounding pharmacy peptides typically cost 3-10x more than research chemical vendors for the same compound and quantity. The premium buys pharmaceutical-grade manufacturing standards, physician oversight, and legal clarity. Whether that premium is worth it depends on individual risk tolerance and use case.

The 2024-2026 GLP-1 compounding saga illustrates how quickly this landscape shifts. During the semaglutide shortage, compounded semaglutide was legally available from hundreds of compounding pharmacies. FDA's declaration that the shortage had ended prompted enforcement actions against compounders, some of whom disputed the shortage declaration. The result: a complex legal environment where compounded GLP-1 availability became state-by-state and pharmacy-by-pharmacy.

Staying current with FDA guidance documents, WADA list updates, and community resources tracking regulatory changes is part of responsible peptide use. What was true 12 months ago may not be accurate today.